<![CDATA[Doxorubicin is one of chemotherapeutic agent used for cancer therapy. However, doxorubicin usage causes some adverse effects, such as lymphocyte, CD4+ and CD8+ cells number.  Therefore,  the  co-chemotherapeutic  agent  is  required  to  reduce  the imunosuppression  effect.  Cardamom  (Elettaria  cardamomum)  contains  terpenoid  1,8  cineol. This  research  aimed  to  know  the  effect  of  Elettaria  cardamomum  distillate  (ECD)  in combination with doxorubicin on Sprague Dawley ratâs hematology profile and the amount of CD4+  and  CD8+  cells.  The  experiment  was  done  for  13  days  using  6  groups  of  rats:  I doxorubicin (dox) 15 mg/kg BW; II dox + ECD5 mg/kg BW; III dox + ECD 50 mg/kg BW; IV dox  +  ECD  100  mg/kg  BW;  V  ECD  100  mg/kg  BW;  VI  control  without  treatment.  The hematology  profile  and  the  amount  of  CD4+  and  CD8+  were  counted  before  and  after treatment  using  flowcytometer.  The  results  show  that  ECD  increases  the  amount  of lymphocyte, white blood, CD4+ and CD8+ cells in dose dependent manner in doxorubicin treated rats. Based on the data, it can be concluded that ECD is potential to be developed as immunostimulant agent for chemotherapy.Keywords: Cardamom (Elettaria cardamomum), immunostimulant, hematology, CD4+, CD8+]]>
Copyrights © 2012
